PORTEFEUILLE

BLEEDnFIRE Therapeutics, a spin-off from the University of Bern, is developing a new medicine called BnF-001 to help people with inherited bleeding disorders like hemophilia A and B, von Willebrand disease, and some rare blood conditions. Most current treatments only manage bleeding when it happens, but they don’t prevent long-term problems like joint damage and bone loss. BnF-001 works in a new way—by gently lowering the activity of a gene in the liver called PROS1, which helps rebalance the blood’s ability to clot. This can reduce the risk of bleeding and protect joints and bones over time, helping patients live healthier, more active lives.

Extensive preclinical data in human plasma, mouse models, and non-human primates have shown that targeting protein S restores thrombin generation, reduces bleeding time, and significantly improves bone structure in hemophilia models. With the support of the GRS InnoBooster grant, BLEEDnFIRE Therapeutics is finalizing the selection of its lead drug candidate, filing a composition of matter patent, and initiating BnF-001 production. These steps will pave the way for IND-enabling studies and prepare the company for its next financing round.
BLEEDnFIRE Therapeutics will continue through pre-IND enabling studies with the aim to enter clinical development within 24–36 months. We are currently preparing for a seed funding round (target CHF 2–3M) and exploring additional non-dilutive sources.